# The 2024 EU AI Act Webinar Scheduled for December 2, 2027, Explaining What the Regulation Means for Healthcare, Drug Development and Medical Devices
- Published: 2026-11-13
- Author: [Healthcare News](https://healthcarenews.io/author/healthcarenews-io.md)
- Topics: [News](https://healthcarenews.io/news.md)
- Source: https://healthcarenews.io/news/the-2024-eu-ai-act-webinar-scheduled-for-december-2-2027-explaining-what-the-regulation-me/
- Publication: Healthcare News
- Publisher: Connectively (Terkel, Inc.)
- Editorial policy: https://healthcarenews.io/editorial-policy/
*Navigate global AI regulation in healthcare with insights on the EU AI Act, high-risk systems, FDA guidance, impact assessments and compliance strategies.*
Dublin, Nov. 13, 2026 [(GLOBE NEWSWIRE)](https://www.globenewswire.com) -- "The 2024 EU AI Act (Dec 2, 2027)" has been added to **ResearchAndMarkets.com's** offering.
Research and Markets has opened registration for “The 2024 EU AI Act”, a 90-minute online course organised by IPI Academy. It takes place live on December 2, 2027. Led by independent consultant Dr. Cheryl Barton, the session explains how the EU AI Act will affect the healthcare sector. This includes how AI systems used in drug development and medical device commercialisation may be classed as high-risk, and what information regulators will require.
**Key Event Facts**
- **Course:** The 2024 EU AI Act
- **Date:** December 2, 2027
- **Time:** 12:00-13:30 GMT
- **Format:** Live online, 90 minutes
- **CPD:** 1 hour
- **Speaker:** Dr. Cheryl Barton
**What the Session Covers**
The session opens with an overview of the EU AI Act and the EU’s Coordinated Plan on Artificial Intelligence, and their potential impact on healthcare. It then explains what makes an AI system high-risk, with examples relevant to drug development and medical device commercialisation. Finally, it sets out the minimum information regulators will require in Fundamental Rights Impact Assessments (FRIAs) and Data Protection Impact Assessments (DPIAs), along with measures for protecting personal data.
**Why You Should Attend**
- Understand the EU AI Act and the EU Coordinated Plan on Artificial Intelligence
- Identify what makes an AI system high-risk in drug development and medical devices
- Learn the minimum information regulators expect in FRIAs and DPIAs
- Review measures for protecting personal data in AI-enabled healthcare
- Gain a concise regulatory briefing in 90 minutes, with 1 CPD hour
**Who Should Attend**
The session is designed for a diverse audience, including healthcare professionals, policymakers and anyone interested in how the EU AI Act will affect the healthcare sector.
**Featured Speaker**
- **Dr. Cheryl Barton**, independent consultant with over 35 years of research and business analysis experience. She has held senior research positions in academia and spent seven years at Merck, and was a senior equity analyst at ABN Amro. She founded PharmaVision in 2002 and writes for Pharmtech.
The session takes place on December 2, 2027. Healthcare, life sciences and policy professionals preparing for the EU AI Act can review the programme and register their interest through Research and Markets.
For more information about this training visit https://www.researchandmarkets.com/r/7jpumt
**About ResearchAndMarkets.com**
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
## Related
- [AI-Assisted Radiation Therapy Planning Software MarketOutlook 2026-2033 | Market to Reach $1.81 Billion as Adaptive Radiotherapy and AI Adoption Accelerate](https://healthcarenews.io/news/ai-assisted-radiation-therapy-planning-software-marketoutlook-2026-2033-market-to-reach-1.md)
- [Global Medical Display Monitors Market Size, Share, and Trends Analysis Report 2026-2033 | AI Imaging and Digital Pathology Propel Market to USD 4 Billion](https://healthcarenews.io/news/global-medical-display-monitors-market-size-share-and-trends-analysis-report-2026-2033-ai.md)
- [U.S. AI-enabled Ophthalmic Diagnostic Devices Market Size, Share, Trends, and Forecast, 2026-2033 | Autonomous Screening Drives 20.5% CAGR and a $267.2 Million Opportunity](https://healthcarenews.io/news/u-s-ai-enabled-ophthalmic-diagnostic-devices-market-size-share-trends-and-forecast-2026-20.md)
- [U.S. Fluoroscopy Procedures Market Report 2026-2033: Size, Share, and Trends by Type, CPT, and End Use | Digital Upgrades Drive 4.1% CAGR to USD 182.7 Million](https://healthcarenews.io/news/u-s-fluoroscopy-procedures-market-report-2026-2033-size-share-and-trends-by-type-cpt-and-e.md)